Efficacy and safety of Shenfu injection treating bradycardia:a systematic review with meta-analysis of randomized controlled trials*
2016, 39 (7):
Objective To evaluate the efficacy and safety of Shenfu injection in the treatment of bradycardia.Methods Randomized controlled trials (RCT) on Shenfu injection treating bradycardiawas retrieved from CNKI database, Wanfang Database,VIP Database,CBM,PubMed, EMbase, and Clinical Trials.gov. Cochrane Handbook was used to assess methodological quality, and data were analyzed using RevMan5.3 Software.Results 13 trials involving 978 patients were included into the analysis. The overall methodological quality was low as most studies were evaluated as B level and one study was C level. Meta-analysis showed that Shenfu injection was better than atropine(RR=1.27, 95％CI 1.09~1.48, P=0.002)in terms of the overall effect (relief of symptoms and improvement of heart rate), but there were no statistic difference between using atropine alone andusing Shenfu injection and atropine together(RR=0.84, 95％CI 0.73～0.97, P=0.30). Compared with Shenfu injection in polarized solution, Shenfu injection can improve the clinical symptoms better(RR=0.52, 95％CI 0.40～0.67, P=0.01), but there was no difference in the heart rate increase (RR=0.57,95％CI 0.32～1.20,P=0.06). Safety:Adverse reactions were reported in four studies, with dry mouth being the most common one. Conclusion In view of the quality of the current research, the efficacy of treating bradycardia with Shenfu injection cannot be ensured. In the future, high quality studies are needed to confirm the efficacy of Shenfu injection.
Related Articles |